In 2019 NHS England updated its clinical pathway for cervical screening, changing the
primary test from cytology to testing for high-risk HPV.
We were asked to help prepare the market for this change by clearly explaining the
impact this update would have on patient referrals to colposcopy clinics, and how the
DYSIS ULTRA technology could help clinics confidently manage new patient cohorts
and a larger overall patient population.
To clearly explain the impact of the new screening program on colposcopy clinics, and how DYSIS ULTRA could support them through this change, we needed to gain a comprehensive understanding of the colposcopy market.
We did this the only way we knew how – by reviewing published clinical data, visiting colposcopy clinics and speaking with practising colposcopists to validate what we had found.
Following several review periods with the DYSIS team, we had a compelling story not only of the impact the new screening pathway would have on patient numbers in the coming years but also of why DYSIS ULTRA is so well positioned to manage this population.
Once the sales aid was complete and reviewed by a senior colposcopist we applied the most relevant parts of it to a brochure to be left with clinics as a convenient reminder.
We use cookies to give you the best online experience. By agreeing you accept the use of cookies in accordance with our cookie policy.
When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.
